SynthesisAdvances in therapy2026

Lipid-Lowering Efficacy and Safety of Oral Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-Analysis.

Walter Masson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.